Seres Therapeutics, Inc. (NASDAQ:MCRB) has earned an average rating of “Buy” from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $37.40.
Several brokerages have recently commented on MCRB. Zacks Investment Research downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 25th. Chardan Capital upgraded shares of Seres Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $27.50 to $30.00 in a report on Thursday, March 11th. Finally, Oppenheimer reiterated a “buy” rating and issued a $38.00 target price on shares of Seres Therapeutics in a report on Tuesday, March 2nd.
Several institutional investors and hedge funds have recently made changes to their positions in MCRB. Orion Capital Management LLC bought a new stake in shares of Seres Therapeutics in the 4th quarter worth approximately $25,000. Meeder Asset Management Inc. purchased a new position in shares of Seres Therapeutics in the first quarter worth $26,000. HM Payson & Co. purchased a new position in shares of Seres Therapeutics in the third quarter worth $28,000. Penserra Capital Management LLC increased its stake in shares of Seres Therapeutics by 174.2% in the fourth quarter. Penserra Capital Management LLC now owns 2,095 shares of the biotechnology company’s stock worth $51,000 after buying an additional 1,331 shares during the period. Finally, Pacer Advisors Inc. purchased a new position in shares of Seres Therapeutics in the fourth quarter worth $133,000. Hedge funds and other institutional investors own 94.32% of the company’s stock.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Monday, March 1st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.05. The firm had revenue of $17.56 million during the quarter, compared to analysts’ expectations of $8.78 million. Seres Therapeutics had a negative net margin of 385.22% and a negative return on equity of 2,867.98%. On average, analysts forecast that Seres Therapeutics will post -1.14 EPS for the current year.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
Featured Article: What is systematic risk?
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.